Tesamorelin (10 Vial Box)

Compliance & Disclaimer

• For Research Use Only
• Not FDA or EMA approved for clinical application
• Evidence is limited to preclinical studies; safety and efficacy in humans remain unestablished.

Tesamorelin is a synthetic 44–amino acid peptide analog of growth hormone–releasing hormone (GHRH), engineered to enhance stability and receptor affinity compared to the endogenous hormone. It binds selectively to GHRH receptors on pituitary somatotrophs, activating a Gs-coupled signaling cascade that stimulates adenylate cyclase, elevates cyclic adenosine monophosphate (cAMP), and activates protein kinase A (PKA). This sequence promotes growth hormone (GH) synthesis and pulsatile release, followed by increased hepatic production of insulin-like growth factor 1 (IGF-1), which mediates downstream anabolic and lipolytic processes. [thepeptidecompany.co], [peptidesciences.com]

Research has focused on Tesamorelin’s role as a model compound for studying GH/IGF-1 axis dynamics, body composition, and lipid metabolism. Preclinical and clinical investigations have documented its ability to modulate visceral adipose tissue (VAT) and hepatic fat fraction under controlled conditions, positioning it as a tool for exploring mechanisms of lipid turnover, adipose redistribution, and metabolic regulation. Studies also report improvements in lipid biomarkers, including reductions in triglycerides and non-HDL cholesterol, while maintaining glucose homeostasis in normoglycemic subjects, though impaired tolerance may occur in susceptible models. [thepeptidecompany.co], [journals.plos.org] [journals.plos.org]

Structural modifications—such as N-terminal acetylation and addition of a trans-3-hexenoic acid group—confer resistance to enzymatic degradation, prolonging Tesamorelin’s activity and supporting its pharmacokinetic profile for research applications. These properties make Tesamorelin a subject of interest in endocrine, metabolic, and aging-related research, with ongoing studies examining its effects on GH pulsatility, IGF-1 signaling, and adipose tissue biology. [biotechpeptides.com] [rawamino.com]

Key Peer-Reviewed References

1. Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial. PLOS ONE. 2017. DOI:10.1371/journal.pone.0179538 [journals.plos.org]
2. Tesamorelin Research Article: GHRH Mechanisms, IGF-1 Regulation & Visceral Fat Reduction Pathways. The Peptide Company. 2025. Link [thepeptidecompany.co]
3. Tesamorelin peptide: lipid metabolism & muscular tissue modulation. Biotech Peptides. 2024. Link [biotechpeptides.com]
4. Tesamorelin: Mechanism and Emerging Applications in Metabolic and Longevity Medicine. Peptide Sciences. 2025. Link [peptidesciences.com]
5. A Research-Centered Comparison of Tesamorelin and Sermorelin. RawAmino. 2025. Link [rawamino.com]